» Articles » PMID: 22524419

Prediction of Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy Using Preoperative Lens Culinaris Agglutinin-reactive Fraction of Alpha-fetoprotein

Overview
Journal Hepatol Res
Specialty Gastroenterology
Date 2012 Apr 25
PMID 22524419
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Aim:   Lens culinaris agglutinin A-reactive fraction of α-fetoprotein (AFP-L3) status has been reported to be an independent prognostic factor in patients with hepatocellular carcinoma (HCC). In this study, we evaluated the clinical usefulness of measuring preoperative AFP-L3 to predict the recurrence and prognosis of HCC after curative hepatectomy.

Methods:   One hundred and forty-two HCC patients who underwent curative hepatectomy were examined for the correlation between preoperative tumor marker, including AFP, des-γ-carboxy prothrombin (DCP) and AFP-L3, and clinicopathological variables. The prognostic factors of disease-free survival rates and overall survival rates were also determined using clinicopathological variables including these three tumor markers.

Results:   There were similar tendencies in the relationship between these three markers and malignant behaviors including lower grade tumor differentiation or vascular invasion. In multivariate analysis, increased AFP-L3 value (P = 0.019) was found to be an independent prognostic factor of disease-free survival after curative hepatectomy. In addition, elevated DCP (P = 0.013) and AFP-L3 values (P = 0.012) were found to be independent prognostic factors. Furthermore, the preoperative AFP-L3 value in the patients with early recurrence (within 1 year after hepatectomy) was significantly higher than that in those without early recurrence (26.9 ± 19.5 % vs 14.2 ± 19.8 %, P = 0.047).

Conclusion:   Preoperative AFP-L3 value was strongly correlated to disease-free and overall survival rate and the timing of recurrence, so it appears that it would be useful to predict the recurrence and prognosis of HCC after curative hepatectomy.

Citing Articles

Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights.

Yu J, Park R, Kim R J Hepatocell Carcinoma. 2023; 10:1105-1127.

PMID: 37483311 PMC: 10362916. DOI: 10.2147/JHC.S341195.


Prognostic value of preoperative protein-induced vitamin K absence or antagonist II after liver resection for hepatitis B-related hepatocellular carcinoma: a nationwide multicenter study.

Byun D, Lee S, Kim H, You Y, Jung J, Jang J Ann Surg Treat Res. 2022; 103(5):271-279.

PMID: 36452307 PMC: 9678661. DOI: 10.4174/astr.2022.103.5.271.


A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.

Jin C, Zhao J, Huang X, Yang X, Niu F, Lin J Hepatol Int. 2022; 16(5):1220-1233.

PMID: 35947245 DOI: 10.1007/s12072-022-10375-y.


Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?.

Rich N, Singal A Hepatology. 2021; 75(3):740-753.

PMID: 34923659 PMC: 8844206. DOI: 10.1002/hep.32284.


FAT10 promotes hepatocellular carcinoma (HCC) carcinogenesis by mediating P53 degradation and acts as a prognostic indicator of HCC.

Zhang Y, Zuo Z, Liu B, Yang P, Wu J, Han L J Gastrointest Oncol. 2021; 12(4):1823-1837.

PMID: 34532131 PMC: 8421874. DOI: 10.21037/jgo-21-374.